| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Innoviva, Inc.$22.24
+0.04 (+0.18%)
B 64Pipeline Score Undervalued Pharma · Commercial
Market Cap
1.66 B
EPS
7.03
P/E Ratio
3.73 $
Value Trade
19.67 M
SEC Financials
Q1 2026Dilution Risk
Revenue
97.99 M
R&D Expenses
5.24 M
Operating CF
35.28 M
Total Assets
1.84 B
Total Liabilities
1.84 B
Equity
1.34 B
D/E Ratio
12,345
-1.62 %
Week
-5.43 %
1 Month
-4.71 %
3 Month
6.45 %
6 Month
70.15 %
5 Year
46.75 %
All Time
Cash Data
Cash Position
1.19 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
2.68 M
52 Week Range
16.52 - 25.15
% held by Insiders
1.25 %
% held by Institutions
103.5 %
Enterprise Value
1.38 B
Total Shares
73.83 M
Short %
9.57 %
Float Shares
69.48 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Innoviva, Inc.
235Total events
0Upcoming
88Tier-1 (high impact)
2013 – 2026Coverage
Event history 235
Jun 16, 2026
▲Partnership / LicenseXACDUROApprovedCorporate
Distribution and licensing agreement with Dr. Reddy's for XACDURO in select international markets
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
2026
▲Timing GuidancePresentation
Anticipated $150 million or more in IST U.S. net product sales in 2026
Q4 2025
▲FDA ApprovalNUZOLVENCEFDA Decision
FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea
uncomplicated urogenital gonorrheasource ↗
Dec 15, 2025
◆PDUFA DatezoliflodacinRegulatory Filing
PDUFA target action date set for December 15, 2025
uncomplicated gonorrheasource ↗
Drug Pipeline Intelligence
B64
Pipeline Score $5.0B
Pipeline ValueUndervalued
Valuation Signal17
Drugs Scored10.0x
rNPV / MCap Top 91%
Micro Cap (rank 83 of 912)
Percentile RankInnoviva, Inc. holds a solid B-grade pipeline (64/100), with $12.4B risk-adjusted pipeline value, led by GCS-100 in Chronic Kidney Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GCS-100 Small molecule | Chronic Kidney Disease | Phase 2 | NCT01717248 | 31% | $6.1B | COMPLETED | 241 | - | - | Jun 1, 2013 | - | Jun 20, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zoliflodacin | uncomplicated gonorrhea | Phase 3 | 2023-11-02 | primary endpoint result: non-inferior to the comparator arm; point estimate: 5.3%; confidence interval: 95% confidence interval: 1.4%, 8.7%; cure rate: >90% Read More | Zoliflodacin Phase 3 clinical trial topline data | |
zoliflodacin | uncomplicated gonorrhea | Phase 3 | 2023-11-02 | primary endpoint result: non-inferior to the comparator arm; point estimate: 5.3%; confidence interval: 95% confidence interval: 1.4%, 8.7%; cure rate: >90% Read More | Zoliflodacin Phase 3 clinical trial topline data | |
zoliflodacin | uncomplicated gonorrhea | Phase 3 | 2023-11-02 | primary endpoint result: non-inferior to the comparator arm; point estimate: 5.3%; confidence interval: 95% confidence interval: 1.4%, 8.7%; cure rate: >90% Read More | Zoliflodacin Phase 3 clinical trial topline data |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INVAInnoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Innoviva Specialty Therapeutics has announced a distribution and licensing agreement with Dr. Reddy’s for XACDURO® in select international markets. This agreement aims to enhance the availability of XACDURO® in these regions. Further details regarding the specific markets and terms of the agreement were not disclosed.
Read more →INVAInnoviva to Participate in Upcoming June 2026 Investor Conferences
Innoviva, Inc. announced its participation in two investor conferences in June 2026, including the Goldman Sachs 47th Annual Global Healthcare Conference and BTIG Infectious Disease Day. The company will engage in a fireside chat and one-on-one meetings to discuss its diversified biopharmaceutical portfolio and strategic investments. A live webcast of the Goldman Sachs event will be available on their website.
Read more →INVAInnoviva to Participate in Upcoming Investor Conferences
Innoviva has announced its participation in upcoming investor conferences. However, specific details regarding the events or the company's agenda were not provided in the announcement. The participation indicates the company's ongoing engagement with investors and stakeholders.
Read more →INVAInnoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva has reported its financial results for the first quarter of 2026, highlighting recent progress made by the company. Specific details regarding financial performance and strategic advancements were not disclosed in the article. The report emphasizes the company's ongoing efforts and developments in the biopharma sector.
Read more →INVAInnoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Innoviva reported strong financial results for Q4 and the full year 2025, with revenues exceeding $400 million and net income surpassing $270 million. The company achieved significant growth in its IST product sales, driven by FDA approval of NUZOLVENCE for gonorrhea treatment. A $125 million share repurchase program was also initiated, highlighting confidence in future growth.
Read more →INVAInnoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, represen
Innoviva, Inc. reported strong financial results for the third quarter of 2025, showcasing $63.4 million in revenue from its royalties portfolio and achieving a 52% year-over-year growth in U.S. net product sales. The company is optimistic about the early market reception for its recently launched antibiotic, ZEVTERA, and is preparing for the upcoming PDUFA date for its investigational drug zoliflodacin. Additionally, Innoviva announced a $125 million share repurchase program, which underscores its confidence in future growth and shareholder value.
Read more →INVAInnoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflec
Innoviva, Inc. reported strong financial results for the second quarter of 2025, showcasing a robust royalties portfolio that generated $67.3 million in revenue. The company achieved U.S. net product sales of $29 million, reflecting a significant 54% growth compared to the previous year. The acceptance of the zoliflodacin NDA by the FDA with a Priority Review is a notable regulatory milestone, with a target action date set for December 15, 2025. Additionally, Innoviva launched ZEVTERA, marking a significant advancement in the treatment of MRSA-related infections.
Read more →INVAInnoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved
Innoviva, Inc. reported its financial results for the first quarter of 2025, showcasing a solid performance with $61.3 million in revenue from its royalty platform. The company experienced a 52% year-over-year increase in net product sales attributed to its therapeutic products. Key developments include the NDA filing for zoliflodacin and the expected commercial launch of ZEVTERA by mid-2025. However, despite the strong sales growth, Innoviva also reported a net loss of $46.6 million for the quarter, raising concerns regarding market volatility.
Read more →INVAInnoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 mi
Innoviva, Inc. (NASDAQ: INVA) reported its fourth quarter and full year 2024 financial results, showcasing a robust performance with significant revenue growth from its core royalty platform and specialty therapeutics business. The company achieved U.S. net product sales of $24.9 million for the fourth quarter, reflecting a 47% increase compared to the previous year. Innoviva also highlighted its acquisition of exclusive U.S. rights to ZEVTERA, which is set to launch in mid-2025. CEO Raifeld expressed optimism about continued growth in 2025, supported by strong financial positioning and a promising product pipeline.
Read more →INVAInnoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviv
Innoviva, Inc. reported robust financial results for the third quarter of 2024, highlighting increases in revenue from its core royalty platform and commercial products. GSK royalties reached $60.5 million with a 6% increase year-over-year. The company's specialty therapeutics segment, including products like GIAPREZA and XACDURO, saw impressive growth, with net product sales climbing to $19.7 million, a 68% increase compared to the previous year. Looking ahead, Innoviva plans to submit a New Drug Application for zoliflodacin in early 2025.
Read more →INVAInnoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IS
Innoviva, Inc. reported its financial results for the second quarter of 2024, highlighting robust growth across its royalty portfolio and commercial products. The company achieved significant revenue with $67.2 million in royalties from GSK and a 38% year-over-year increase in net product sales, totalling $21.7 million. Additionally, key products like XACDURO received recognition in treatment guidelines, indicating their importance in critical care. However, Innoviva also faced a net loss for the quarter, raising concerns about future profitability amidst increasing expenses.
Read more →INVACorporate Presentation May 2024 Forward - looking statements The information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Secti
Innoviva's corporate presentation details forward-looking statements regarding its strategy, operations, and financial positions. The company highlights its cashflow-positive royalty business, which derives from widely used respiratory products, alongside a robust therapeutics platform. However, the presentation also emphasizes significant risks and uncertainties that may impede achieving projected goals. These include potential declines in future royalties and the timing of product commercialization.
Read more →INVAInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, represent
Innoviva, Inc. reported its financial results for the first quarter of 2024, showcasing a robust performance driven by a significant increase in royalties and product revenues. The company generated net product revenues of $19.1 million, marking a 66% growth compared to the previous year. Additionally, the positive Phase 3 trial results for zoliflodacin emphasize the potential of its pipeline products. Innoviva plans to submit a New Drug Application for zoliflodacin in early 2025 and continues to focus on enhancing shareholder value through prudent investments and cost discipline.
Read more →INVAInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter Achieved net product rev
Innoviva, Inc. reported its financial results for Q4 and full year 2023, showcasing significant achievements including a 35% year-on-year growth in product revenues. The company successfully launched XACDURO for Acinetobacter infections and reported positive Phase 3 data for the oral drug zoliflodacin. Innoviva ended the year with over $275 million in cash and receivables, reinforcing its strong financial position. The company's leadership emphasizes a focus on driving long-term shareholder value through disciplined financial strategies and innovative therapeutics.
Read more →INVA▲ +6.9%on this news
Zoliflodacin Phase 3 clinical trial topline data
The Phase 3 clinical trial of zoliflodacin revealed positive topline results, demonstrating its efficacy in treating uncomplicated gonorrhea. The drug met its primary efficacy endpoint, showing comparable microbiological cure rates to the standard treatment of ceftriaxone and azithromycin. Safety data indicated that zoliflodacin was well-tolerated with a majority of adverse events being mild. This promising data positions zoliflodacin as a potential new therapeutic option amidst rising antimicrobial resistance.
Read more →INVAInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-i
Innoviva, Inc. reported its third quarter financial results for 2023, highlighting a gross royalty revenue of $57.0 million and net product revenues of $13.7 million. The company successfully launched XACDURO for treating specific bacterial pneumonias and announced positive topline data from the Phase 3 trial of zoliflodacin aimed at treating gonorrhea. However, net income saw a notable decline compared to the same quarter last year, reflecting diminished one-time gains from prior sales. Despite the reduction in income, Innoviva demonstrated operational progress and plans to continue shareholder-friendly policies.
Read more →INVAInnoviva Appoints Stephen Basso as Chief Financial Officer
Innoviva, Inc. has appointed Stephen Basso as Chief Financial Officer, effective August 21, 2023, to leverage his extensive experience in the financial services and pharmaceutical sectors. Basso previously held key positions at Cybrexa Therapeutics and Inozyme Pharma, among others. His appointment is considered strategic as Innoviva aims to capitalize on opportunities for growth and shareholder value.
Read more →INVAInnoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the seco
Innoviva, Inc. reported its financial results for the second quarter of 2023, highlighting a net income of $1.3 million and significant GSK royalties of $65.7 million. The company received FDA approval for XACDURO, enhancing its treatment offerings for hospital-acquired pneumonia. However, gross royalty revenue decreased from the previous year largely due to the divestiture of a subsidiary. Innoviva also engaged in a $25 million investment in Armata Pharmaceuticals to support its therapeutic pipeline and manufacturing facility.
Read more →INVACorporate Presentation May 2023 Forward-looking statementsThe information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
Innoviva's May 2023 corporate presentation outlines its forward-looking statements regarding future operations and financial performance. The company highlights a diversified portfolio of healthcare assets, with significant income generated from its respiratory products. Challenges include the risks of lower than expected royalties from GSK partnerships and commercialization difficulties in approved jurisdictions. Innoviva emphasizes its late-stage pipeline and growth strategies despite uncertainties in achieving its projected objectives.
Read more →INVAInnoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first
Innoviva, Inc. reported its financial results for the first quarter of 2023, highlighting a net income of $34.9 million, which is an increase from the previous year. The company received $60.3 million in royalties from Glaxo Group Limited (GSK), although this represents a decline from the prior year's figures due to the sale of its subsidiary. Additionally, the FDA's Antimicrobial Drugs Advisory Committee gave unanimous support for the approval of sulbactam-durlobactam, which targets serious bacterial infections. Innoviva is focused on cost management and enhancing shareholder value through strategic activities like share repurchases.
Read more →INVAInnoviva Announces Retirement of Board Chairman BURLINGAME, Calif. ( BUSINESS WIR E ) Innoviva, Inc. (NASDAQ: INVA) ( Innoviva and the Company ) and George Bickerstaff, III, Chairman of the Board of Directors of the Comp
Innoviva, Inc. announced that Board Chairman George Bickerstaff, III will not seek reelection at the upcoming annual meeting. Bickerstaff, who has served since 2017, is stepping down to focus on other professional and philanthropic endeavors, including his role with the International Vaccine Institute. The CEO of Innoviva praised Bickerstaff's contributions and the company's continued progress during his leadership. Following the meeting, the board will consist of six members, assuming all other directors are reelected.
Read more →INVAInnoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress Royalties of $54.7 million in the fourth quarter of 2022 for RELVAR /BREO ELLIPTA and ANORO ELLIPTA Net product sales of $14.6
Innoviva, Inc. reported its financial results for Q4 2022, revealing a mixed performance with a decrease in global net sales for RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Despite this decline, the company noted significant progress in its infectious disease business, particularly with recent acquisitions. The FDA has accepted the SUL-DUR NDA with Priority Review, reflecting potential growth opportunities. Overall net income dropped sharply compared to the previous year, raising concerns about future performance.
Read more →INVAInnoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress Royalties at $65.6 million in the third quarter of 2022, compared to $65.7 million in the same quarter of 2021, for RELVAR /BRE
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress Royalties at $65.6 million in the third quarter of 2022, compared to $65.7 million in the same quarter of 2021, for RELVAR /BREO ELLIPTA and ANORO ELLIPTA Announced new $100.0 milli
Read more →INVAItem 1A. Risk Factors The information presented below supplements the risk factors set forth in Item 1A of Part I of our 2021 Form 10-K. Except as set forth below, for additional risk factors that could cause actual resu
Item 1A. Risk Factors The information presented below supplements the risk factors set forth in Item 1A of Part I of our 2021 Form 10-K. Except as set forth below, for additional risk factors that could cause actual results to differ materially from those anticipated, please r
Read more →INVAInnoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acqu
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress BURLINGAME, Calif.-(BUSINESS WIRE)-Jul. 27, 2022-Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and a growi
Read more →INVAInnoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment BURLINGAME, Calif., July 13, 2022 -- Innoviva, Inc. (Nasda
Read more →INVAInnoviva Completes Acquisition of Entasis Therapeutics BURLINGAME, Calif. - (BUSINESS WIRE)
Innoviva Completes Acquisition of Entasis Therapeutics BURLINGAME, Calif. - (BUSINESS WIRE) -- July 11, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of
Read more →INVAInnoviva to Acquire La Jolla Pharmaceutical Company Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA (R) and XERAVA (R) BURLINGAME, Calif. and
Innoviva to Acquire La Jolla Pharmaceutical Company BURLINGAME, Calif. and WALTHAM, Mass. - July 11, 2022 - Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceu
Read more →INVAExecution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this " Agreement "), dated as of
TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this "Agreement"), dated as of May 23, 2022, is entered into by and among Innoviva, Inc., a Delaware corporation ("Parent"), Innoviva Merger Sub, Inc., a Delaware corporation and wholly owned Subsidiary of Parent (
Read more →INVAInnoviva Reports First Quarter 2022 Financial Results Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028
Innoviva Reports First Quarter 2022 Financial BURLINGAME, Calif., April 27, 2022 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Pavel Raifeld, Chief Executive Officer of Innoviva, Inc
Read more →INVAInnoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes Proceeds expected to be used to repurchase a portion of the 2023 Notes, fund capped call transactions, and for general corporate purposes
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes BURLINGAME, Calif., March 2, 2022--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other fact
Read more →INVAInnoviva Reports Fourth Quarter 2021 Financial Results Royalties increased by 18% to $111.1 million in the fourth quarter of 2021, compared to the same quarter in 2020; royalties increased by 19% to $405.7 million in ful
Innoviva Reports Fourth Quarter 2021 Financial BURLINGAME, Calif., February 9, 2022 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the fourth quarter and the year ended December 31, 2021. Pavel Raifeld, Chief Executive Offi
Read more →INVACorporate Presentation December 2021 Forward - looking statements The information in this presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended (
Corporate Presentation December 2021 Forward - looking statements The information in this presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended ("Securities Act"), and Section 21 E of the Securities Excha
Read more →INVAInnoviva Reports Third Quarter 2021 Financial Results Royalties increased by 10% to $101.3 million in the third quarter of 2021, compared to the same quarter in 2020.
Third Quarter 2021 Financial Results October 27, 2021 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the third quarter ended September 30, Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated, "Our royalty reven
Read more →INVAInnoviva Reports Second Quarter 2021 Financial Results Royalties increased by 44% to $104.3 million in the second quarter of 2021, compared to the same quarter in 2020. Repurchased GSK's full 32% equity stake in Innoviva
Innoviva Reports Second Quarter 2021 Financial BURLINGAME, Calif., July 28, 2021 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the second quarter ended June 30, 2021. Pavel Raifeld, Chief Executive Officer of Innoviva, Inc
Read more →INVAInnoviva Reports First Quarter 2021 Financial Results Royalties increased by 8% to $89.0 million in the first quarter of 2021, compared to the same quarter in 2020. Invested an additional $20.0 million into Armata Pharma
First Quarter 2021 Financial Results Calif., April 28, 2021 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2021. Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: "Our royal
Read more →INVAInnoviva Reports Fourth Quarter 2020 Financial Results Royalties increased by 18% to $93.9 million in the fourth quarter of 2020, compared to the same quarter in 2019. Invested $300 million into a fund advised by Sarissa
Reports Fourth Quarter 2020 Financial Results BURLINGAME, Calif., February 3, 2021 - Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: "RELVA
Read more →INVAInnoviva Reports Third Quarter 2020 Financial Results Royalties increased by 33% to $92.2 million in the third quarter of 2020, compared to the same quarter in 2019. Invested an additional $12.5 million into the common s
Innoviva Reports Third Quarter 2020 Financial BURLINGAME, Calif., October 28, 2020 - Innoviva, Inc. (NASDAQ: INVA) (the "Company") today reported financial results for the third quarter ended Raifeld, Chief Executive Officer of Innoviva, Inc., stated: "RELVAR /BREO net sales
Read more →INVAInnoviva Reports Second Quarter 2020 Financial Results Royalties increased by 7% to $72.4 million in the second quarter of 2020, compared to the same quarter in 2019. Pavel Raifeld named as Chief Executive Officer. Inves
Reports Second Quarter 2020 Financial Results Calif., July 29, 2020 - Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2020. Raifeld, Chief Executive Officer, stated: "RELVAR /BREO net sales decreased by 3% com
Read more →INVAInnoviva Reports First Quarter 2020 Financial Results Total net revenue increased by 43% to $78.7 million in the first quarter of 2020, compared to the same quarter in 2019. Income before income taxes increased by 96% to
Reports First Quarter 2020 Financial Results BURLINGAME, Calif., April 29, 2020 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva", or the "Company") today reported financial results for the first quarter ended March 31, 2020. net sales of RELVAR /BREO 31% versus the first quarter
Read more →INVAINNOVIVA ANNOUNCES CHANGE OF LOCATION OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 24, 2020
ANNOUNCES CHANGE OF LOCATION OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 24, 2020 Calif - March 31, 2020 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company") announced today that, due to the public health impact of the coronavirus pandemic, the location of
Read more →INVAInnoviva Reports Fourth Quarter 2019 Financial Results Total net revenue decreased by 4.9% to $76.0 million in the fourth quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased by 3.9
Innoviva Reports Fourth Quarter 2019 BURLINGAME, Calif., February 5, 2020 - Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, net sales of RELVAR /BREO 18% versus the fourth quarter of 2018. U.S. net sales d
Read more →INVAInnoviva Reports Third Quarter 2019 Financial Results Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to
Reports Third Quarter 2019 Financial Results BRISBANE, Calif., October 30, 2019 - Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the third quarter ended September net sales of RELVAR /BREO 10% versus the third quarter of 2018. U.S. net sales
Read more →INVAInnoviva Reports Second Quarter 2019 Financial Results Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly
Innoviva Reports Second Quarter 2019 Financial Results Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared
Read more →INVAInnoviva Reports First Quarter 2019 Financial Results Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to
Innoviva Reports First Quarter 2019 Financial Results Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to th
Read more →INVAInnoviva Reports Fourth Quarter 2018 Financial Results Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017. 1 Income before income taxes increased 25% from t
Innoviva Reports Fourth Quarter 2018 Financial Results Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017.1 Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million. BRISBANE, Cali
Read more →INVAInnoviva Reports Third Quarter 2018 Financial Results Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third
Innoviva Reports Third Quarter 2018 Financial Results Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million, or $0.43 per diluted sh
Read more →INVAInnoviva Reports Second Quarter 2018 Financial Results Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the sec
Innoviva Reports Second Quarter 2018 Financial Results Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million, or $0.49 per diluted
Read more →INVAINNOVIVA NAMES GEOFFREY HULME AS INTERIM PRINCIPAL EXECUTIVE OFFICER ************ Hulme to execute capital allocation review and cost cutting initiatives of the board; will also oversee investigation into conduct of advi
INNOVIVA NAMES GEOFFREY HULME AS INTERIM PRINCIPAL EXECUTIVE OFFICER Hulme to execute capital allocation review and cost cutting initiatives of the board; will also oversee investigation into conduct of advisors to the board in connection with 2017 proxy contest Brisbane, CA,
Read more →INVAInnoviva Reports First Quarter 2018 Financial Results Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quar
Innoviva Reports First Quarter 2018 Financial Results Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million, or $0.29 per basic share. B
Read more →INVAIssued
Issued: April 24, 2018, London UK LSE Announcement Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administrati
Read more →INVAInnoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results Royalties earned of $70.5 million in the fourth quarter of 2017, up 51% from the fourth quarter of 2016. Royalties earned in 2017 reached $227.9
Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results Royalties earned of $70.5 million in the fourth quarter of 2017, up 51% from the fourth quarter of 2016. Royalties earned in 2017 reached $227.9 million, up 56% from 2016. Net income attributable to In
Read more →INVAIssued: 26 January 2018 London UK and Brisbane, Calif. LSE Announcement GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma GlaxoSmithKline plc (LSE/NYSE:GSK)
Issued: 26 January 2018 London UK and Brisbane, Calif. LSE Announcement GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medi
Read more →INVAInnoviva and Sarissa Implement Court Order Appoints George Bickerstaff, III and Odysseas Kostas, M.D. to the Board Brisbane, Calif.
Innoviva and Sarissa Implement Court Order Appoints George Bickerstaff, III and Odysseas Kostas, M.D. to the Board Brisbane, Calif. December 19, 2017 Innoviva, Inc. (the Company or Innoviva ) (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery s order e
Read more →INVAInnoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates Royalties earned in the third quarter of 2017 of $51.9 million, up 42% from the third quarter of 2016. Completed the full refinancing of
Innoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates Royalties earned in the third quarter of 2017 of $51.9 million, up 42% from the third quarter of 2016. Completed the full refinancing of the 9% non-recourse term notes due 2029. Plans to repurc
Read more →INVAIssued: 19 September 2017, London UK GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations Trelegy Ellipta met
Issued: 19 September 2017, London UK GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared
Read more →INVAIssued: 18 September 2017, London UK LSE Announcement Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US GlaxoSmithK
Issued: 18 September 2017, London UK LSE Announcement Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announc
Read more →INVAIssued: 15 September 2017, London UK LSE Announcement Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD GlaxoSmith
Issued: 15 September 2017, London UK LSE Announcement Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announ
Read more →INVAInnoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half Brisbane, Calif.
Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half Brisbane, Calif. August 21, 2017 Innoviva, Inc. ( Innoviva or the Company ) (NAS
Read more →INVAInnoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers $17.5 million Over-Allotment Option
Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers $17.5 million Over-Allotment Option BRISBANE, Calif., August 7, 2017 Innoviva, Inc. (NASDAQ: INVA) (the Company or Innoviva ) today announced that i
Read more →INVAInnoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes
Innoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes BRISBANE, Calif., August 1, 2017 Innoviva, Inc. (NASDAQ: INVA) (the Company or Innoviva ) today announced the pricing of $175 million aggregate principal amount of the Company s 2.50% convertible se
Read more →INVAInnoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes
Innoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes BRISBANE, Calif., July 31, 2017 Innoviva, Inc. (NASDAQ: INVA) (the Company or Innoviva ) today announced its intention to offer, subject to market conditions and other factors, $175 million aggregat
Read more →INVAInnoviva Reports Strong Second Quarter 2017 Financial Results Royalties earned up 73% and net income up 141% compared to second quarter of 2016 Management to host a conference call and webcast today at 5:00 p.m. eastern
Innoviva Reports Strong Second Quarter 2017 Financial Results Royalties earned up 73% and net income up 141% compared to second quarter of 2016 Management to host a conference call and webcast today at 5:00 p.m. eastern time. BRISBANE, Calif., July 26, 2017 Innoviva, Inc. (NAS
Read more →INVARelvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care Significant improvement in asthma control was seen at all time points measured across the s
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care Significant improvement in asthma control was seen at all time points measured across the study GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc. (NASDAQ: INVA
Read more →INVAIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SARISSA CAPITAL DOMESTIC FUND LP, SARISSA OFFSHORE MASTER FUND LP, SARISSA CAPITAL FUND GP LLC, SARISSA CAPITAL FUND GP LP, SARISSA CAPITAL OFFSHORE FUND LP LLC, SARISSA
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SARISSA CAPITAL DOMESTIC FUND LP, SARISSA OFFSHORE MASTER FUND LP, SARISSA CAPITAL FUND GP LLC, SARISSA CAPITAL FUND GP LP, SARISSA CAPITAL OFFSHORE FUND LP LLC, SARISSA CAPITAL MANAGEMENT GP LLC, SARISSA CAPITAL MANAGEMENT LP, :
Read more →INVAInnoviva Reports First Quarter 2017 Financial Results Royalties earned in Q1 2017 of $43.7 million, up 60% from Q1 2016 Net income for Q1 2017 of $16.8 million (up 280% from Q1 2016), or $0.16 basic earnings per share, a
Innoviva Reports First Quarter 2017 Financial Results Royalties earned in Q1 2017 of $43.7 million, up 60% from Q1 2016 Net income for Q1 2017 of $16.8 million (up 280% from Q1 2016), or $0.16 basic earnings per share, and adjusted earnings per share of $0.19 per share Managem
Read more →INVAInnoviva Announces $50 Million Partial Royalty Notes Redemption Accelerated Notes Redemption Resulting from the Company s Continuing Growth in Royalty Revenue and Cash Flows Brisbane, Calif.
Innoviva Announces $50 Million Partial Royalty Notes Redemption Accelerated Notes Redemption Resulting from the Company s Continuing Growth in Royalty Revenue and Cash Flows Brisbane, Calif., April 10, 2017 Innoviva, Inc. (the Company or Innoviva ) (Nasdaq: INVA) today announce
Read more →INVAInnoviva Files Preliminary Proxy Materials for 2017 Annual Meeting Current Board s Strategic Plan has Produced Increased Royalty Revenue, Reduced Operating Expenses and Increased Net Income While Growing Stockholder Retu
Innoviva Files Preliminary Proxy Materials for 2017 Annual Meeting Current Board s Strategic Plan has Produced Increased Royalty Revenue, Reduced Operating Expenses and Increased Net Income While Growing Stockholder Returns Sarissa Has Nominated a Slate to Replace a Majority of
Read more →INVAIssued: Thursday 23 February 2017 London UK LSE Announcement Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma LONDON & BRISBANE, Calif. (BUSINESS WIRE) GlaxoSm
Issued: Thursday 23 February 2017 London UK LSE Announcement Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma LONDON & BRISBANE, Calif. (BUSINESS WIRE) GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today anno
Read more →INVAInnoviva Reports Fourth Quarter and Full Year 2016 Financial Results 2016 royalties earned up 119% vs. 2015 Royalties earned in Q4 2016 of $46.8 million, up 80% from Q4 2015 Net income for Q4 2016 of $25.5 million, or $0
Innoviva Reports Fourth Quarter and Full Year 2016 Financial Results 2016 royalties earned up 119% vs. 2015 Royalties earned in Q4 2016 of $46.8 million, up 80% from Q4 2015 Net income for Q4 2016 of $25.5 million, or $0.24 per share, and adjusted earnings per share of $0.26 p
Read more →INVAGSK files regulatory submission in European Union for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD LONDON and Brisbane, Calif.
GSK files regulatory submission in European Union for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD LONDON and Brisbane, Calif. December 2, 2016 GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by G
Read more →INVARelvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD LONDON and Brisbane, Calif.
Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD LONDON and Brisbane, Calif. December 1, 2016 GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has
Read more →INVAIssued: Monday, 21 November 2016, London UK LSE Announcement GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD GlaxoSmithKline plc (LSE
Issued: Monday, 21 November 2016, London UK LSE Announcement GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing
Read more →INVAInnoviva Reports Third Quarter 2016 Financial Results Q3 2016 royalty revenue earned up 118% vs Q3 2015 Net income of $15.0 million, or $0.14 per share, and adjusted earnings per share of $0.17 per share Appointed Patric
Innoviva Reports Third Quarter 2016 Financial Results Q3 2016 royalty revenue earned up 118% vs Q3 2015 Net income of $15.0 million, or $0.14 per share, and adjusted earnings per share of $0.17 per share Appointed Patrick G. LePore as a director of Innoviva Management will ho
Read more →INVAPA4629 Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: results of the FULFIL trial Lomas D1, Lipson D2,3, Barnacle H4, Birk R4, Brealey N4, Zhu C-Q5, Tabberer M6 1UCL Respiratory, University
PA4629 Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: results of the FULFIL trial Lomas D1, Lipson D2,3, Barnacle H4, Birk R4, Brealey N4, Zhu C-Q5, Tabberer M6 1UCL Respiratory, University College London, London, UK; 2Respiratory Research and Devel
Read more →INVAPositive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress London and Brisbane, Calif.
Positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress London and Brisbane, Calif. September 4, 2016 GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the results from the pi
Read more →INVAInnoviva Reports Second Quarter 2016 Financial Results Royalty revenues rose 157% compared to Q2 2015, to $35.7 million U.S. TRx market share recently reached all-time highs of 10% for BREO and 8% for ANORO Net income of
Innoviva Reports Second Quarter 2016 Financial Results Royalty revenues rose 157% compared to Q2 2015, to $35.7 million U.S. TRx market share recently reached all-time highs of 10% for BREO and 8% for ANORO Net income of $14.6 million, or $0.13 per share, and Adjusted Cash EPS
Read more →INVAIssued: Monday 20 June 2016, London UK LSE Announcement FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohaler in improving lung function and health-relat
Issued: Monday 20 June 2016, London UK LSE Announcement FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohaler in improving lung function and health-related quality of life in COPD patients Data supports regulatory submission
Read more →INVARegulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD - Acceleration of filing of US New Drug Application now expected by end of 2016 London and South S
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD - Acceleration of filing of US New Drug Application now expected by end of 2016 London and South San Francisco - June 2, 2016 GlaxoSmithKline plc (LSE:GSK) and Innoviva,
Read more →INVASalford Lung Study results show COPD patients treated with Relvar Ellipta achieve superior reduction in exacerbations compared to usual care Pioneering GSK study provides important new data on the effective
Salford Lung Study results show COPD patients treated with Relvar Ellipta achieve superior reduction in exacerbations compared to usual care Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice M
Read more →INVANew York-Presbyterian Hospital/Weil Cornell Medical Center, New York, NY, USA; 2University of Michigan Health System, Ann Arbor, MI, USA; 3GSK R&D, Stockley Park, Middlesex, UK 4Brigham and Women s Hospital, Harvard Medi
1New York-Presbyterian Hospital/Weil Cornell Medical Center, New York, NY, USA; 2University of Michigan Health System, Ann Arbor, MI, USA; 3GSK R&D, Stockley Park, Middlesex, UK 4Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA; 5GSK R&D, Research Triangle Pa
Read more →INVAInnoviva Reports First Quarter 2016 Financial Results Including: Royalty revenues of $27.4 million, a 171% increase compared to Q1 2015 37% quarter over quarter growth in U.S. prescriptions for RELV
Innoviva Reports First Quarter 2016 Financial Results Royalty revenues of $27.4 million, a 171% increase compared to Q1 2015 37% quarter over quarter growth in U.S. prescriptions for RELVAR/BREO ELLIPTA Net income of $4.4 million, or $0.04 per share, and Adjusted Cash EPS of $
Read more →INVAINNOVIVA March 2016 Safe Harbor 2 2016 INNOVIVA This presentation contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things,
2016 INNOVIVA March 2016 Safe Harbor 2 2016 INNOVIVA This presentation contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and
Read more →INVAInnoviva reports Fourth Quarter and Full Year 2015 Financial Results Company reports its first quarterly net income, generating $4.3 million in Q4 2015 Repurchased approximately $37 million of stock through the end of Ja
Innoviva reports Fourth Quarter and Full Year 2015 Financial Results Company reports its first quarterly net income, generating $4.3 million in Q4 2015 Repurchased approximately $37 million of stock through the end of January 2016 Company to host conference call and webcast to
Read more →INVATheravance, Inc. Announces Name Change to Innoviva, Inc. South San Francisco, Calif. (
Theravance, Inc. Announces Name Change to Innoviva, Inc. South San Francisco, Calif. (January 8, 2016) Theravance, Inc. (NASDAQ: THRX), a healthcare-focused asset management company, today announced that it changed its name to Innoviva, Inc., effective January 7, 2016. In additi
Read more →INVATheravance Reports Third Quarter 2015 Financial Results US BREO ELLIPTA sales up by more than 40% in U.S. market quarter over quarter Initiates a $150 million stock repurchase program to accelerate the company s capital
Theravance Reports Third Quarter 2015 Financial Results US BREO ELLIPTA sales up by more than 40% in U.S. market quarter over quarter Initiates a $150 million stock repurchase program to accelerate the company s capital return plan Announces intent to launch a modified Dutch a
Read more →INVAEffect of Umeclidinium/Vilanterol (UMEC/VI) on Inspiratory Capacity/Total Lung Capacity Ratio in Hyperinflated COPD Patients Poster No. PA1493 Singh S(1), Maltais F(2), Tombs L(3), Church A(4), Iqbal A(4), Riley JH(5) (1
Singh S(1), Maltais F(2), Tombs L(3), Church A(4), Iqbal A(4), Riley JH(5) (1) Centre for Exercise and Rehabilitation Science, University Hospital of Leicester NHS Trust, Glenfield Hospital, Leicester, UK; (2)Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pne
Read more →INVAIssued: Thursday 24 September, 2015, London UK and South San Francisco, CA, USA - LSE Announcement Regulatory update: GSK and Theravance announce intention to file Relvar Ellipta for COPD in Japan GlaxoSmit
Issued: Thursday 24 September, 2015, London UK and South San Francisco, CA, USA - LSE Announcement Regulatory update: GSK and Theravance announce intention to file Relvar Ellipta for COPD in Japan GlaxoSmithKline (LSE/NYSE:GSK) and Theravance, Inc. (NASDAQ: THRX) today announce
Read more →INVAIssued: 8 September 2015, London, UK and South San Francisco, CA, USA LSE announcement GSK and Theravance announce results from the SUMMIT COPD CV Survival Study GlaxoSmithKline plc (LSE/NYSE: GSK) and Ther
Issued: 8 September 2015, London, UK and South San Francisco, CA, USA LSE announcement GSK and Theravance announce results from the SUMMIT COPD CV Survival Study GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced initial results from the Stu
Read more →INVAIssued: 6th August, 2015 (Mississauga) GSK receives approval for BREO ELLIPTA for the treatment of adults with asthma GSK and Theravance, Inc. announce the approval in Canada of BREO ELLIPTA (fluticasone fu
Issued: 6th August, 2015 (Mississauga) GSK receives approval for BREO ELLIPTA for the treatment of adults with asthma GSK and Theravance, Inc. announce the approval in Canada of BREO ELLIPTA (fluticasone furoate/vilanterol dry powder for oral inhalation) for the once-daily main
Read more →INVATheravance Reports Second Quarter 2015 Financial Results Theravance declares a $0.25 per share dividend for Q3 2015 Theravance to host conference call and webcast today at 5:00 p.m.
Theravance Reports Second Quarter 2015 Financial Results Theravance declares a $0.25 per share dividend for Q3 2015 Theravance to host conference call and webcast today at 5:00 p.m. EDT SOUTH SAN FRANCISCO, Calif., July 29, 2015 Theravance, Inc. (NASDAQ: THRX) today reported f
Read more →INVATheravance, Inc. Appoints Michael Faerm as Chief Business Officer
Theravance, Inc. Appoints Michael Faerm as Chief Business Officer SOUTH SAN FRANCISCO, Calif., July 13, 2015 Theravance, Inc. (NASDAQ: THRX) today announced the appointment of Michael E. Faerm as Senior Vice President and Chief Business Officer. Mr. Faerm reports directly to Mic
Read more →INVACan Dual Long-acting Bronchodilator Therapy Prevent Clinically Important Deteriorations In Chronic Obstructive Pulmonary Disease? A Post Hoc Analysis Of The ZEP117115 Trial Poster No. Singh D(1), Maleki-Yazdi R(2), Tombs
Can Dual Long-acting Bronchodilator Therapy Prevent Clinically Important Deteriorations In Chronic Obstructive Pulmonary Disease? A Post Hoc Analysis Of The ZEP117115 Trial Singh D(1), Maleki-Yazdi R(2), Tombs L(3), Naya I(3), Church A(4), Iqbal A(4) (1)University of Mancheste
Read more →INVAThe Effect of Reducing Lung Hyperinflation with Fluticasone Furoate/Vilanterol on Cardiac Structure, Function and Arterial Stiffness: A Cardiac Magnetic Resonance Study Ian S Stone, Neil C Barnes, Wai-Yee James, Dawn ,Mi
Pulmonary Function FF/VI 100/25 vs Placebo FEV (l) FVC (l) FEV/FVC (%) Residual Volume (l) Difference 0.220 0.350 2.0 -0.429 95% CI 0.12, 0.31 0.21, 0.49 -0.3, 4.3 -0.59, -0.27 P-value <0.001* <0.001* 0.092 <0.001* Analysis performed using an ANCOVA model with covariates of treat
Read more →INVATheravance Reports First Quarter 2015 Financial Results Theravance declares a $0.25 per share dividend for Q2 2015 Theravance to host conference call and webcast today at 5:00 p.m.
Theravance Reports First Quarter 2015 Financial Results Theravance declares a $0.25 per share dividend for Q2 2015 Theravance to host conference call and webcast today at 5:00 p.m. EDT SOUTH SAN FRANCISCO, Calif., May 6, 2015 Theravance, Inc. (NASDAQ: THRX) today reported fina
Read more →INVAIssued: Thursday 30 April 2015, London, UK, and South San Francisco, CA, USA LSE Announcement FDA approves BREO ELLIPTA for the treatment of adults with asthma in the US GlaxoSmithKline plc (LSE: GSK) and T
Issued: Thursday 30 April 2015, London, UK, and South San Francisco, CA, USA LSE Announcement FDA approves BREO ELLIPTA for the treatment of adults with asthma in the US GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug
Read more →INVAIssued: 19 March 2015, London, UK, and South San Francisco, CA, USA GSK and Theravance announce outcome of US FDA Advisory Committee on BREO ELLIPTA in asthma GlaxoSmithKline plc (LSE: GSK) and Theravance,
Issued: 19 March 2015, London, UK, and South San Francisco, CA, USA GSK and Theravance announce outcome of US FDA Advisory Committee on BREO ELLIPTA in asthma GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the outcome of the joint meeting of
Read more →INVAEfficacy and safety of once-daily umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two replicate randomized 12-week studies Thomas M. Siler Midwest Chest Consultan
Serial FEV1 showed a rapid onset of FEV1 improvements (statistically significant at the first measured timepoint of 15 minutes) with both doses of UMEC+FF/VI in both studies vs PBO+FF/VI, which was maintained through to Day 84 (all p<0.001). 0 23 24 1 Study 1 Study 2 Time (h) 0.3
Read more →INVAEfficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol (FSC) combination twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations James F. Do
Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol (FSC) combination twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations James F. Donohue, MD, FCCP Department of Medicine, University of North
Read more →INVAUmeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Poster No. P290 Singh D,(1) Worsle
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Singh D,(1) Worsley S,(2) Zhu C-Q,(2) Hardaker L,(2) Church A(3) (1)University of Manchester
Read more →INVAFOR HEALTHCARE PROFESSIONAL MEDIA ONLY Issued: 9 July, 2014 - Sydney, Australia Anoro Ellipta (umeclidinium/vilanterol) approved in Australia for Chronic Obstructive Pulmonary Disease - Administered using a
Issued: 9 July, 2014 - Sydney, Australia Anoro Ellipta (umeclidinium/vilanterol) approved in Australia for Chronic Obstructive Pulmonary Disease GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Therapeutic Goods Administration (TGA) in Australi
Read more →INVATheravance, Inc. and Theravance Biopharma, Inc. Announce Completion of Separation of Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations SOUTH SAN FRANCISCO, CA (MARKETWIRED JUNE 2, 2014) Theravance
Theravance, Inc. and Theravance Biopharma, Inc. Announce Completion of Separation of Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations SOUTH SAN FRANCISCO, CA (MARKETWIRED JUNE 2, 2014) Theravance, Inc. (NASDAQ: THRX) ( Theravance ) and Theravance Bioph
Read more →INVAA. Nicholls, M.D., Ph.D. Theravance, Inc. 901 Gateway Blvd. South San Francisco, CA 94080 Phone: 650-808-3928 anicholls@theravance.com A Randomized, Crossover, 7-day Study of Once-daily TD-4208, a Long-Acting Muscarinic
A. Nicholls, M.D., Ph.D. Theravance, Inc. 901 Gateway Blvd. South San Francisco, CA 94080 Phone: 650-808-3928 anicholls@theravance.com A Randomized, Crossover, 7-day Study of Once-daily TD-4208, a Long-Acting Muscarinic Antagonist (LAMA) in Subjects with COPD A. Nic
Read more →INVAEfficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma Poster #407 Bernstein DI(1), Bateman ED(2), Woodcock A(3), Toler WT(4), Forth R(5), Jacques
Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) and FF over 12 weeks in patients with persistent asthma Bernstein DI(1), Bateman ED(2), Woodcock A(3), Toler WT(4), Forth R(5), Jacques L(6), Nunn C(6), O Byrne PM(7) (1)College of Medicine, University of
Read more →INVAPoster Board No. 411 Bronchodilator response to the long-acting bronchodilator combination of umeclidinium/vilanterol across subgroups of patients with COPD MeiLan K. Han(1), Chris Kalberg(2), Jean Brooks(3), Alison Chur
Poster Board No. 411 Bronchodilator response to the long-acting bronchodilator combination of umeclidinium/vilanterol across subgroups of patients with COPD MeiLan K. Han(1), Chris Kalberg(2), Jean Brooks(3), Alison Church(2) (1)Division of Pulmonary Medicine, University of Mi
Read more →INVAPoster #406 APS 2014, Tampa, FL rvickery@theravance.com Axelopran Phase 2b Study Demonstrates a Sustained Increase in Bowel Movement Frequency in Patients Regardless of Duration of Opioid-Induced Constipation Ross Vicker
rvickery@theravance.com Axelopran Phase 2b Study Demonstrates a Sustained Increase in Bowel Movement Frequency in Patients Regardless of Duration of Opioid-Induced Constipation Ross Vickery, PhD(1), Lynn Webster, MD(2), Yu-Ping Li, PhD(1), Neil Singla, MD(3), and Daniel Canafax
Read more →INVATheravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia 20 mg Dose Met the Primary Endpoint Showing Significant Improvement in Weekly Average Pain Score and Met Both Secondary
Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia 20 mg Dose Met the Primary Endpoint Showing Significant Improvement in Weekly Average Pain Score and Met Both Secondary Efficacy Endpoints SOUTH SAN FRANCISCO, CA (MARKETWIRED AP
Read more →INVAFor medical media Issued: 22 April 2014, Sydney Australia Breo Ellipta (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and Chronic Obstructive Pulmonary Disease - Fir s t combi
Issued: 22 April 2014, Sydney Australia Breo Ellipta (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and Chronic Obstructive Pulmonary Disease GSK Australia and Theravance, Inc. (NASDAQ: THRX) announced today that the Therapeutic Goods Administrati
Read more →INVATheravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process Proceeds Intended to Accelerate Capital Return Strategy for Proposed Royalty Management Company
Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process Proceeds Intended to Accelerate Capital Return Strategy for Proposed Royalty Management Company SOUTH SAN FRANCISCO, CA, April 21, 2014 Theravance, Inc. (NASDAQ: THRX) (the
Read more →INVATheravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations Separation Expected to be Completed in Second Quarter 2014 SOUTH SAN FRANCISCO, CA (Marketwir
Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations Separation Expected to be Completed in Second Quarter 2014 SOUTH SAN FRANCISCO, CA (Marketwired March 3, 2014) Theravance, Inc. (NASDAQ: THRX) announc
Read more →INVAFOR MEDICAL AND TRADE MEDIA 08.01.14, London UK The first once-daily ICS/LABA treatment for asthma and COPD launches in the UK GlaxoSmithKline (GSK) and Theravance, Inc (NASDAQ: THRX) today announce the launch of RELVAR
FOR MEDICAL AND TRADE MEDIA The first once-daily ICS/LABA treatment for asthma and COPD launches in the UK GlaxoSmithKline (GSK) and Theravance, Inc (NASDAQ: THRX) today announce the launch of RELVAR ELLIPTA (fluticasone furoate/vilanterol) in the UK, the first inhaled cortico
Read more →INVAANORO ELLIPTA approved for COPD treatment in Canada Approved as a new once-daily dual bronchodilator for the treatment of COPD in Canada Mississauga, ON - January 9 , 2014 - GlaxoSmithKline Inc. and Therava
ANORO ELLIPTA approved for COPD treatment in Canada Approved as a new once-daily dual bronchodilator for the treatment of COPD in Canada Mississauga, ON - January 9, 2014 - GlaxoSmithKline Inc. and Theravance Inc. today announced that ANORO ELLIPTA was approved in Canada on Dec
Read more →INVAThe efficacy and safety of inhaled fluticasone furoate (FF)/vilanterol (VI) in Asian patients with COPD Jinping Zheng1; Teresita de Guia2; Jie Wang-Jairaj3; Amy H Newlands3; Changzheng Wang4; Chin-chou Wang5; Courtney Cr
Thorax 2011;66:425 9; 2Jones PW. et al. Eur Respir J 2009;34:648 54 COPD Assessment Test (CAT) Adverse events (AEs) Placebo (n=162) FF/VI 50/25 (n=160) FF/VI 100/25 (n=161) FF/VI 200/25 (n=160) Any on-treatment AE 63 (39) 64 (40) 59 (37) 77 (48) Any serious AE 14 (9) 9 (6) 7 (4)
Read more →INVAPOSTER NO. PS108 Efficacy and safety of once-daily fluticasone furoate/vilanterol 200/25mcg compared with twice-daily fluticasone propionate 500mcg in asthma patients of Asian ancestry Jiangtao L(1), Crawford J(2), Jacqu
Efficacy and safety of once-daily fluticasone furoate/vilanterol 200/25mcg compared with twice-daily fluticasone propionate 500mcg in asthma patients of Asian ancestry Jiangtao L(1), Crawford J(2), Jacques L(3), Stone S(3) (1)Department of Respiratory Diseases, China-Japan Frie
Read more →INVAPoster No. P3640 Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Marc Decramer,(1) Antonio Anzueto,(2) Edward Kerwin,(3) Nathalie Richard,(4) Glenn Crater,(4) Maggie Tabber
Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Marc Decramer,(1) Antonio Anzueto,(2) Edward Kerwin,(3) Nathalie Richard,(4) Glenn Crater,(4) Maggie Tabberer,(5) Stephanie Harris,(4) Alison Church(4) (1)University Hospital, Leuven
Read more →INVAPoster No. P760 Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD James Donohue,(1) Dennis Niewoehner,(2) Jean Brooks,(3) Dianne O Dell,(4) Alison Church(4) (1)University of North Caro
Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD James Donohue,(1) Dennis Niewoehner,(2) Jean Brooks,(3) Dianne O Dell,(4) Alison Church(4) (1)University of North Carolina, North Carolina, USA; (2)VA Medical Center, Minneapolis, USA; (3)Glax
Read more →INVAMedicines That Make a Difference NASDAQ: THRX
Theravance assumes no obligation to update its forward-looking statements. 2 Safe Harbor Randomized, double-blind, placebo-controlled, multicenter, incomplete block 5-period cross-over study 62 patients with moderate to severe COPD 6 doses of TD-4208 (22, 44, 88,175, 350 and 700
Read more →INVABREO ELLIPTA APPROVED FOR COPD TREATMENT IN CANADA Mississauga, ON
BREO ELLIPTA APPROVED FOR COPD TREATMENT IN CANADA Mississauga, ON - July 10, 2013 - BREO ELLIPTA (fluticasone furoate/vilanterol) has been approved in Canada for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary
Read more →INVAQualitative assessment of a two-strip dry powder inhaler (ELLIPTA ) for COPD and asthma Poster No. 1976 Woepse M(1), Dale P(2), Garrill K(3), Svedsater H(4), Walker R(5) (1)Strategic Eye, Inc., Wayne, PA, USA; (2)HEOR So
Qualitative assessment of a two-strip dry powder inhaler (ELLIPTA ) for COPD and asthma Woepse M(1), Dale P(2), Garrill K(3), Svedsater H(4), Walker R(5) (1)Strategic Eye, Inc., Wayne, PA, USA; (2)HEOR Solutions, London, UK; (3)Medicine and Process Delivery, (4)Global Health O
Read more →INVATheravance, Inc. Calls for Redemption of $172.5 Million of 3% Convertible Subordinated Notes Due 2015 (CUSIP No. 88338T AA2) SOUTH SAN FRANCISCO, CA (Marketwired
Theravance, Inc. Calls for Redemption of $172.5 Million of 3% Convertible Subordinated Notes Due 2015 (CUSIP No. 88338T AA2) SOUTH SAN FRANCISCO, CA (Marketwired June 4, 2013) Theravance, Inc. (NASDAQ: THRX), a biopharmaceutical company with a pipeline of internally discovered
Read more →INVAPOSTER NO. G16 Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on COPD exacerbations: a pre-specified subgroup analysis Dransfield MT(1), Calverley PMA(2), Bourbeau J(3), Jones P(4), Hanania NA(5), Ma
Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on COPD exacerbations: a pre-specified subgroup analysis Dransfield MT(1), Calverley PMA(2), Bourbeau J(3), Jones P(4), Hanania NA(5), Mahler DA(6), Vestbo J(7), Wachtel A(8), Martinez F(9), Barnhart F(10), Midw
Read more →INVAPOSTER NO. 806 Once-daily (OD) fluticasone furoate/vilanterol 100/25mcg (FF/VI) compared with twice-daily (BD) fluticasone propionate/salmeterol 250/50mcg (FSC) in patients with COPD Dransfield M(1), Crim C(2), Feldman G
Once-daily (OD) fluticasone furoate/vilanterol 100/25mcg (FF/VI) compared with twice-daily (BD) fluticasone propionate/salmeterol 250/50mcg (FSC) in patients with COPD Dransfield M(1), Crim C(2), Feldman G(3), Korenblat P(4), LaForce C(5), Locantore N(2), Pistolesi M(6), Watkins
Read more →INVALong-acting bronchodilators and arterial stiffness in patients with COPD POSTER NO. 225 D.B. Rubin (1), J.-L. Pepin(2), J.R. Cockcroft(3), D. Midwinter(4), S. Sharma(1), S. Andreas(5) (1)GlaxoSmithKline - Research Triang
Long-acting bronchodilators and arterial stiffness in patients with COPD D.B. Rubin(1), J.-L. Pepin(2), J.R. Cockcroft(3), D. Midwinter(4), S. Sharma(1), S. Andreas(5) (1)GlaxoSmithKline - Research Triangle Park/US; (2)Joseph Fourier University and Grenoble University Hospital
Read more →INVAPoster 376 APS2013, New Orleans, LA rvickery@theravance.com TD-1211 Demonstrates Tolerability and Clinical Activity Following Multiple Treatment Administration Strategies in Patients with Opioid-Induced Constipation Neil
APS2013, New Orleans, LA rvickery@theravance.com TD-1211 Demonstrates Tolerability and Clinical Activity Following Multiple Treatment Administration Strategies in Patients with Opioid-Induced Constipation Neil Singla(1), Daniel Canafax(2), Angela Kang(2), Yu-Ping Li(2), Ullri
Read more →INVATHERAVANCE ANNOUNCES CLOSING OF PUBLIC OFFERING OF $287.5
THERAVANCE ANNOUNCES CLOSING OF PUBLIC OFFERING OF $287.5 MILLION OF CONVERTIBLE SUBORDINATED NOTES SOUTH SAN FRANCISCO, CA. January 24, 2013 Theravance, Inc. (NASDAQ: THRX) (the Company ), a biopharmaceutical company with a pipeline of internally discovered product candidates
Read more →INVATHERAVANCE ANNOUNCES PRICING OF CONVERTIBLE SUBORDINATED NOTES OFFERING Company has also entered into Capped Call Transactions in connection with the Notes Offering
THERAVANCE ANNOUNCES PRICING OF CONVERTIBLE SUBORDINATED Company has also entered into Capped Call Transactions in connection with the Notes Offering SOUTH SAN FRANCISCO, CA. January 17, 2013 Theravance, Inc. (NASDAQ: THRX) (the Company ), a biopharmaceutical company with a pip
Read more →Competitive Position
How INVA ranks across every disease it competes inCompetitive Position is a premium feature
See how INVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial